NCT04463953 2026-02-11
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
Clinical Trials
41 trialsNCT02389517 2026-01-22
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Phase 2 Completed
NCT02619682 2026-01-08
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02461888 2025-12-17
MUKEight
University of Leeds
Phase 2 Completed
NCT02412228 2025-10-15
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Brown University
Phase 2 Completed
NCT03731832 2025-09-30
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
GWT-TUD GmbH
Phase 2 Completed
NCT01415882 2025-09-05
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
Phase 2 Completed
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT02765854 2025-06-26
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
Phase 2 Completed
NCT03012880 2025-06-04
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01718743 2025-01-28
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03399539 2024-11-04
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT02633059 2024-09-19
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT04217967 2024-08-01
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
Peking Union Medical College Hospital
Phase 4 Completed
NCT02697383 2024-05-13
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02586038 2024-05-08
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
University of Turin, Italy
Phase 2 Completed
NCT04028115 2024-04-03
BONE
Odense University Hospital
Phase 2 Completed
NCT02119468 2024-03-15
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT03323151 2024-01-18
PrE0404
PrECOG, LLC.
Phase 1/2 Completed
NCT03506360 2024-01-09
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT03202628 2023-09-21
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01936532 2023-08-03
IFM2013-06
Nantes University Hospital
Phase 2 Completed
NCT02942095 2023-04-18
Study of Ixazomib and Erlotinib in Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03236792 2022-09-29
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT02582359 2022-08-24
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
Massachusetts General Hospital
Phase 1 Completed
NCT02042989 2022-07-11
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02169791 2021-09-02
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Northside Hospital, Inc.
Phase 2 Completed
NCT02499081 2021-06-11
UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
University of Arkansas
Phase 2 Completed
NCT02630030 2021-03-26
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
Emory University
Phase EARLY_PHASE1 Completed
NCT02831686 2020-11-24
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02504359 2020-11-23
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02477215 2020-10-22
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1/2 Completed
NCT02400437 2020-09-02
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02168101 2020-02-27
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02410694 2019-12-13
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT02057640 2019-12-11
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT02070458 2018-12-13
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02406144 2017-11-30
Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma
PETHEMA Foundation
Phase 3 Completed
NCT02158975 2017-11-13
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
University of Michigan Rogel Cancer Center
Phase 2 Completed